171 filings
Page 5 of 9
8-K
acnuh iv12aess2w7
8 Dec 20
Regulation FD Disclosure
4:14pm
8-K
eioq5cb 50ikfxul
4 Dec 20
Departure of Directors or Certain Officers
4:12pm
8-K
ihjrff9q2s9ssk8ga
9 Nov 20
Tricida Announces Third Quarter 2020 Financial Results
4:18pm
8-K
ciy4rv
29 Oct 20
Cost Associated with Exit or Disposal Activities
7:39am
8-K
22evi41t541u3wqc
24 Aug 20
Tricida Receives Complete Response Letter from the FDA for its New Drug Application for Veverimer for the Treatment of Metabolic Acidosis and Slowing of Kidney Disease Progression in Patients with Metabolic Acidosis Associated with CKD
8:41am
8-K
gw4 n6mwu0ex
5 Aug 20
Tricida Announces Second Quarter 2020 Financial Results
4:11pm
8-K
dv7zvt208ey5
15 Jul 20
Tricida Provides Regulatory Update on Veverimer
5:10pm
8-K
7ztlpcfxougp6h
30 Jun 20
Departure of Directors or Certain Officers
4:14pm
8-K
dtwvng
16 Jun 20
Amendments to Articles of Incorporation or Bylaws
4:43pm
DEFA14A
05caw1pj a2c0fbfzoo
3 Jun 20
Additional proxy soliciting materials
5:16pm
8-K
atgr7g2uplpact2yko3
22 May 20
Entry into a Material Definitive Agreement
4:57pm
8-K
27ekh jbcyt9w8i1sxt
20 May 20
Tricida Announces Proposed Offering of $175 Million Convertible Senior Notes Due 2027
6:12am
8-K
0cwzdvt my7
19 May 20
Entry into a Material Definitive Agreement
8:16am
8-K
mdla984s
7 May 20
Tricida Announces First Quarter 2020 Financial Results
4:16pm
DEFA14A
xry34csa
29 Apr 20
Additional proxy soliciting materials
4:11pm
PRE 14A
4zpw8sjq78pu
17 Apr 20
Preliminary proxy
4:05pm